U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Gd
Molecular Weight 157.2521
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 3

SHOW SMILES / InChI
Structure of GADOLINIUM CATION (3+)

SMILES

[Gd+3]

InChI

InChIKey=RJOJUSXNYCILHH-UHFFFAOYSA-N
InChI=1S/Gd/q+3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/

DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.

CNS Activity

Curator's Comment:: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27169
Gene ID: 5444.0
Gene Symbol: PON1
Target Organism: Homo sapiens (Human)
105.0 mM [Ki]
Target ID: P52209
Gene ID: 5226.0
Gene Symbol: PGD
Target Organism: Homo sapiens (Human)
73.0 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DOTAREM

Approved Use

Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Launch Date

1.36373758E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
PubMed

PubMed

TitleDatePubMed
Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism.
1994 Sep
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors.
1997 May
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations.
2002 Jun 1
Gadolinium-containing contrast media for radiographic examinations: a position paper.
2002 Oct
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium.
2004 May
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
2005 Apr 20
Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C.
2006 Apr 28
Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
2006 Feb
Renal safety of gadolinium-based contrast agent for ionizing radiation imaging.
2006 Jul
Loss of primary cilia results in deregulated and unabated apical calcium entry in ARPKD collecting duct cells.
2006 Jun
Gadolinium-based contrast media for multi-detector row spiral CT pulmonary angiography in patients with renal insufficiency.
2006 Mar
Gadolinium-based contrast agents and nephrotoxicity.
2006 Nov
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
2008 Apr
Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
2008 Aug
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008 Jul
Gadolinium and kidney disease: are your patients at risk?
2008 Mar-Apr
Speciation analysis of gadolinium-based MRI contrast agents in blood plasma by hydrophilic interaction chromatography/electrospray mass spectrometry.
2008 Nov 1
Renal failure and gadolinium. The number of documented cases is rising.
2008 Oct
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency.
2009 Dec
Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch.
2009 Dec
Large sample of nephrogenic systemic fibrosis cases from a single institution.
2009 Oct
Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity.
2010 Aug
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture.
2010 Mar
Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
2010 Nov
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
2011 Feb 18
Heavy metal cations permeate the TRPV6 epithelial cation channel.
2011 Jan
Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.
2013 Apr
Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.
2015 Dec
MR Angiography at 3 T of Peripheral Arterial Disease: A Randomized Prospective Comparison of Gadoterate Meglumine and Gadobutrol.
2015 Jun
Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.
2015 Mar
The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
2015 Sep
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
2016 Mar
Patents

Sample Use Guides

Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight. Administer as an intravenous bolus injection. Follow injection with a normal saline flush.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
GADOLINIUM CATION (3+)
Common Name English
GADOLINIUM, ION (3+)
Common Name English
GADOLINIUM CATION
Common Name English
GADOLINIUM ION
Common Name English
Classification Tree Code System Code
NDF-RT N0000183362
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
Code System Code Type Description
RXCUI
1546429
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB14578
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
PRIMARY
CAS
22541-19-1
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
PRIMARY
PUBCHEM
168050
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
PRIMARY
FDA UNII
AZV954TZ9N
Created by admin on Sat Jun 26 04:08:24 UTC 2021 , Edited by admin on Sat Jun 26 04:08:24 UTC 2021
PRIMARY